[A phase II study of Futraful suppository in head and neck cancer]. 1988

M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
Dept. of Otorhinolaryngology, Kagoshima University Hospital.

A phase II study of FT-207 suppository (Futraful Suppository) for head and neck cancer was conducted at the Kagoshima University Hospital Dept. of Otorhinolaryngology and its 6 affiliated hospitals. Forty cases with head and neck cancer were entered in the trial, of which 37 were perfectly evaluable. Partial response (PR) (16.7%) was achieved in one of 6 patients with maxillary cancer, in 2 of 9 cases with oral cancer (22.2%), in one of 7 with laryngeal cancer (14.3%), in 3 of 13 with pharyngeal cancer, while 2 of the same 13 achieved a complete response (CR) (38.5%), for a total response rate of 24.3%. FT-207 suppository was continuously administered as standard, at a dose of 750 mg each twice daily, or 1,500 mg/day. The response rate was dose-dependent; 2 CR cases with a total dose of 105 g for administration over a total period of more than 150 days. Adverse effects appearing in 35.0% of the overall were mainly anorexia, nausea and vomiting; none of them, however, were serious.

UI MeSH Term Description Entries
D008297 Male Males
D008444 Maxillary Sinus Neoplasms Tumors or cancer of the MAXILLARY SINUS. They represent the majority of paranasal neoplasms. Cancer of Maxillary Sinus,Maxillary Sinus Cancer,Neoplasms, Maxillary Sinus,Cancer, Maxillary Sinus,Cancers, Maxillary Sinus,Maxillary Sinus Cancers,Maxillary Sinus Neoplasm,Neoplasm, Maxillary Sinus
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207

Related Publications

M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
February 1987, American journal of clinical oncology,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
September 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
July 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
June 1984, American journal of clinical oncology,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
March 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
April 1988, European journal of cancer & clinical oncology,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
January 1990, Acta oncologica (Stockholm, Sweden),
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
April 1999, Seminars in radiation oncology,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
February 1983, Nihon Gan Chiryo Gakkai shi,
M Ohyama, and M Matsumura, and K Katsuta, and T Nobori, and S Furuta, and S Matsunaga, and A Uchizono, and T Hanada, and I Moriyama, and S Kamachi
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!